TELEFLEX INC

NYSE: TFX·Wayne, Pennsylvania·

Price
$157.10
Base IV
$114.95

Valuation snapshot

Above base case

At $157.10, the price sits between our base case ($114.95) and bull case ($174.83).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$114.95
73% of the price · range $58.19–$174.83
Price vs base case
37% above
$157.10 against $114.95
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has risen 3.3% since this valuation was struck on 2026-11-06, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $58.19 to bull $174.83. Values per share.

Price against each value

Bear case
$58.19
Price 170% above
No growth
…
—
Base case
$114.95
Price 37% above
Researched bygemini-3.8-flash-medium
Valuation Nov 6, 2026 · Price as of Nov 16, 2026How we got here

What does Teleflex do?

Teleflex designs and manufactures single-use medical devices for hospitals and healthcare providers to perform diagnostic and therapeutic procedures in critical care and surgical applications.

It brought in $2.3B of sales in the 12 months to Sep 2026.

MANTA vascular closure device at a femoral arterial access siteImage: Teleflex
Industry
Healthcare
Based in
Wayne, Pennsylvania
Trades on
NYSE as TFX

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 14¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 42¢ of every dollar.

  • Making what it sells42¢
  • Research and development8¢
  • Sales, marketing and admin39¢
  • Everything else it takes to operate2¢
  • Interest and other costs4¢
  • Tax1¢
  • Left as profit14¢
  • Other items after tax came back in+10¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Teleflex, and for what?

Teleflex makes medical devices, mostly single-use, for procedures in hospitals and other care settings. It sells them worldwide through its own sales teams and distributors, earning revenue when customers buy its products.

Hospitals and other healthcare providers buy Teleflex products directly or through distributors.

  • Americas

    64%

    Medical technology products sold in North, Central and South America.

  • EMEA

    24%

    Medical technology products sold in Europe, the Middle East and Africa.

  • Asia

    12%

    Medical technology products sold in the Asia Pacific region.

    MANTA vascular closure device at a femoral arterial access siteImage: Teleflex
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Chihuahua manufacturing facility — Chihuahua, Mexico. Teleflex lists a 153,000-square-foot owned manufacturing facility here, its largest disclosed manufacturing facility outside properties classified as held for sale.
  • Tecate manufacturing facility — Tecate, Mexico. Its 172,000-square-foot owned plant is one of Teleflex’s largest disclosed manufacturing facilities and a significant part of its Mexican production footprint.
  • Bülach manufacturing facility — Bülach, Switzerland. The facility develops and produces balloon catheters and drug-coated stent systems for Teleflex’s interventional portfolio.
  • Žďár nad Sázavou manufacturing facility — Žďár nad Sázavou, Czech Republic. This facility manufactures and assembles catheter-based medical devices and breathing circuits, including products associated with Teleflex’s Arrow vascular-access brand.
  • Maple Grove engineering and research center — Maple Grove, United States. Teleflex’s 103,000-square-foot owned engineering and research facility provides substantial space for medical-device development.
See them on the globe

Teleflex 2025 Form 10-K

How is the business doing?

Sales shrank from $2.5B in 2020 to $2B in 2025, about 5% a year.

Running the business leaves about 9¢ of each sales dollar as operating profit, down from 17¢ in 2020.

After paying for its upkeep and new investment, it had $243M of cash to spare in the 12 months to Sep 2026.

Sales$2B
20162025
Operating margin6%
20162025
Free cash flow$1.4M
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Teleflex says its purpose is to improve people’s health and quality of life.

“Improve the health and quality of peoples’ lives.”

Teleflex: Our Values

What management says it is working on now:

  • Focus the business portfolio

    Teleflex is reshaping the company around its remaining medical technology businesses through planned sales of Acute Care and Interventional Urology.

    Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
  • Integrate the vascular intervention business

    Teleflex is integrating the business acquired from BIOTRONIK, including aligning sales and administrative teams and moving some manufacturing to lower-cost locations.

    Teleflex 2025 Form 10-K
  • Improve efficiency and reduce costs

    The company is restructuring its remaining operations and supply chain, with a plan to remove costs and improve its longer-term cost structure.

    Teleflex 2025 Form 10-K
  • Grow core product categories

    Teleflex is emphasizing vascular, interventional and surgical products, supported by new products, broader use of existing technologies and expansion into markets.

    Teleflex 2025 Form 10-K
2026 continuing-operations revenue growth, 2026
13.4% to 14.4% reported; 3.5% to 4.5% on a pro forma adjusted constant-currency basis
Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
2026 adjusted diluted earnings per share from continuing operations, 2026
$6.90 to $7.20
Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
Annual pre-tax savings from the Vascular Intervention integration plan, Once fully implemented; actions expected to be substantially complete by the end of 2028
$24 million to $30 million
Teleflex 2025 Form 10-K
Annual pre-tax savings from the Strategic Divestitures restructuring plan, Once fully implemented; plan expected to be substantially complete by mid-2028
$48 million to $52 million
Teleflex 2025 Form 10-K
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q3 2026 it sold 0% more than a year earlier. The year before, quarters averaged 31%.

Its operating margin is wider than a year ago: 19¢ per sales dollar, against a loss of 11¢.

Since Oct 2026 the share price has risen 11%, from $141.39 to $157.10.

Bull $174.83Base $114.95Bear $58.19Oct 30Nov 16 · $157.10
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • Second half of 2026

    Expected sale of Acute Care and Interventional Urology businesses

    The transactions remain subject to customary approvals and closing conditions; Teleflex expects them to close in the second half of 2026.

    Teleflex 2025 Form 10-K
  • 2026

    EU medical device certification work

    Teleflex expects its products to meet EU Medical Device Regulation requirements in 2026, with registration work and related spending also expected to finish that year.

    Teleflex 2025 Form 10-K
  • April 6, 2026 or April 5, 2027, depending on facility

    Ethylene oxide sterilizer compliance deadlines

    Contract sterilizers must meet new emissions standards by April 6, 2026, or April 5, 2027, depending on facility circumstances; disruption could affect product supply.

    Teleflex 2025 Form 10-K

Our own estimate moved too: the base case went from $21.21 to $114.95 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Divestitures may be delayed or disrupt operations

    The Acute Care and Interventional Urology sales depend on approvals and other closing conditions. Separation work could distract leaders or strain ties with customers, suppliers and employees.

    From the company's own filingsWould hit how fast sales growTeleflex 2025 Form 10-K

  2. The smaller business may not replace sales from units being sold

    After the sales, Teleflex will rely on a narrower set of products. If remaining or new products do not make up for the revenue and profit being sold, results could suffer.

    From the company's own filingsWould hit how fast sales growTeleflex 2025 Form 10-K

  3. Medical device competition and product development

    Competitors may offer better features, results or value. New products may take substantial investment and may not win regulatory clearance or customer acceptance.

    From the company's own filingsWould hit how fast sales growTeleflex 2025 Form 10-K

  4. Regulatory requirements can delay sales or raise costs

    Medical devices face extensive review and quality rules across countries. Delays, inspection findings or failure to meet certification requirements could limit sales or interrupt production.

    From the company's own filingsWould hit how fast sales growTeleflex 2025 Form 10-K

  5. Sterilization interruptions could restrict supply

    Many products need sterilization before sale, and some rely on outside providers using ethylene oxide. New emissions rules or facility interruptions could reduce the supply of products if alternatives are not available in time.

    From the company's own filingsWould hit how fast sales growTeleflex 2025 Form 10-K

  6. Pricing and costs can pressure margins

    Healthcare cost controls may lead buyers or public programs to seek lower prices. Tariffs, labor and material costs, logistics, and currency changes can also raise costs or reduce margins.

    From the company's own filingsWould hit how much of each sale it keepsTeleflex 2025 Form 10-K

  7. Third quarter 2026 reported revenue from continuing operations grew 0.2% on a reported basis and Interventional revenue declined 2.6%.

    From our researchWould hit how fast sales growTeleflex Reports Third Quarter 2026 Results

  8. Operating margin experienced sharp dips in Q3 2025 (-11.0%) and Q1 2026 (3.7%) due to portfolio transition headwinds.

    From our researchWould hit how much of each sale it keepsTeleflex Form 10-K Filing

Is it a good business?

From 2016 to 2025 it earned between 2% and 11% on the capital invested in it, a median of 7%. Its cost of capital in the latest valuation is 7.9%; returns were above it in 4 of the 10 years.

From 2016 to 2025 it earned between -29% and 15% on its shareholders' equity, a median of 9%.

Over 10 years its operating margin ranged from 6¢ to 22¢ per sales dollar, a median of 17¢. Gross margin ran from 52¢ to 61¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital2%
20162025

Cost of capital 7.9%

Return on equity-29%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 12%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 5.9% in a year, so each remaining share owns a slightly bigger slice.

It owes $1.2B more than it holds in cash, about 5.6 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $157.10. Our put its value between $58.19 and $174.83, with $114.95 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $58.19

This scenario assumes Teleflex faces prolonged pricing pressure in vascular access and slower hospital procedural volumes following portfolio divestitures, keeping revenue growth near 2% and limiting profitability recovery.

Base case, $114.95

This scenario assumes Teleflex delivers on management's guided 3.5% to 4.5% core sales growth by expanding its vascular and surgical device lines while expanding profit margins toward 20%.

Bull case, $174.83

This scenario assumes breakthrough products like bioresorbable scaffolds accelerate sales growth to 6% while operational leverage and favorable product mix push profit margins to 24%.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 37%

For Teleflex to be worth today's $157.10, sales would need to grow about 10.0% a year. We assume 4.0%. Over the last 5 years, sales shrank 3.9% a year.

−10%−5%0%+5%+10%+15%Past 5 yrs −3.9%We assume 4.0%Price needs 10.0%

Or, if sales grow 4.0% as we assume, the price works with a profit margin of 25.9% (we assume 20.0%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 10.0% a year?

Try your own numbers

We're moderately sure of this range: it scores 58 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $114.95 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average4.0%
  • Operating margin20.0%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$114.95 -26.8%

Build